<DOC>
	<DOCNO>NCT02677246</DOCNO>
	<brief_summary>Children treat bone marrow transplantation ( BMT ) experience bone toxicity . Those bone damage cause decrease bone formation increase bone destruction BMT.For long term survivor , bone complication major determinant impair quality life . No standard treatment currently exist prevent bone injury . Denosumab treatment specifically block bone destruction 4 6 month adults . This trial study whether safe prescribe Denosumab child BMT aim prevent bone complication .</brief_summary>
	<brief_title>Denosumab Prevention Bone Complications After Bone Marrow Transplantation Children</brief_title>
	<detailed_description>Participant receive one subcutaneous dose Denosumab within 2 week confirmation bone marrow engraftment . The dose treatment escalate participant . Denosumab suppose effective several month ( 4 6 month ) . The biologic activity Denosumab follow measure blood biomarker bone destruction call CTX . This biomarker suppose decrease Denosumab infusion , reflect blockade bone destruction treatment . Bone density assess radiologic test name DXA standard test . All blood radiologic test mandate study do time standard follow-up bone marrow transplant . Thus , participant extra visit outpatient clinic , extra blood puncture , specific purpose study . Participants follow 36 month bone marrow transplantation.For experience graft versus host disease , second dose Denosumab allow , follow subsequent dos evry 4 6 month till maximum 4 dos within 24months bone marrow transplantation .</detailed_description>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Age 2 year 21 year Allogenic hematopoietic stem cell transplantation ( alloHSCT ) plan within 1 month . Informed consent sign participant 18 year old , parent his/her legal guardian Teeth examination dentist order rule treat latent teeth infection alloHSCT Refusal signing inform consent Prior inclusion another therapeutic trial time elapse last research drug dose Denosumab , short 7 halflifes research drug Osteopetrosis Bisphosphonates treatment within 12 month enter trial Tooth infection treat alloHSCT Childbearing breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>Children</keyword>
	<keyword>Bone complication</keyword>
	<keyword>Denosumab .</keyword>
</DOC>